

Date: 17<sup>th</sup> March, 2022

To,  
The Manager,  
Listing Department,  
National Stock Exchange of India Limited  
"Exchange Plaza",  
Bandra Kurla Complex, Bandra (E),  
Mumbai – 400 051

Dear Sir/Madam,

**Sub: Submission under Regulation 57(1) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**

**Ref: ISIN - INE901L08039, NSE Scrip Code: Alembic Pharma 8.37% 2022 (Sr. Tranche III)**

We hereby certify that the Company has made payment of interest and redemption of principal to the holder(s) of 8.37% Unsecured Listed Rated Redeemable Non-Convertible Debentures ('NCDs') of the Company holding NCDs under the **ISIN – INE901L08039** on 17<sup>th</sup> March, 2022 i.e. immediately preceding business day from due date i.e. 18<sup>th</sup> March, 2022.

We request you to kindly take the same on record.

Thanking you,

Yours faithfully,  
**For Alembic Pharmaceuticals Limited**

**Charandeep Singh Saluja**  
Company Secretary

**ALEMBIC PHARMACEUTICALS LIMITED**

REGD. OFFICE : ALEMBIC ROAD, VADODARA - 390 003, INDIA • TEL : +91-265-2280550 • FAX : +91-265-2282837

Website : [www.alembicpharmaceuticals.com](http://www.alembicpharmaceuticals.com) • E-mail : [alembic@alembic.co.in](mailto:alembic@alembic.co.in)

CIN : L24230GJ2010PLC061123